DVC1-0101 to Treat Peripheral Arterial Disease: A Phase I/IIa Open-label Dose-escalation Clinical Trial

作者：Yonemitsu Yoshikazu^*; Matsumoto Takuya; Itoh Hiroyuki; Okazaki Jin; Uchiyama Makiko; Yoshida Kumi; Onimaru Mitsuho; Onohara Toshihiro; Inoguchi Hiroyuki; Kyuragi Ryoichi; Shimokawa Mototsugu; Ban Hiroshi; Tanaka Michiko; Inoue Makoto; Shu Tsugumine; Hasegawa Mamoru; Nakanishi Yoichi; Maehara Yoshihiko

来源：Molecular Therapy, 2013, 21(3): 707-714.

DOI：10.1038/mt.2012.279

We here report the results of a Phase I/IIa open-label four dose-escalation clinical study assessing the safety, tolerability, and possible therapeutic efficacy of a single intramuscular administration of DVC1-0101, a new gene transfer vector based on a nontransmissible recombinant Sendai virus (rSeV) expressing the human fibroblast growth factor-2 (FGF-2) gene (rSeV/dF-hFGF2), in patients with peripheral arterial disease (PAD). Gene transfer was done in 12 limbs of 12 patients with rest pain, and three of them had ischemic ulcer(s). No cardiovascular or other serious adverse events (SAEs) caused by gene transfer were detected in the patients over a 6-month follow-up. No infectious viral particles, as assessed by hemagglutination activity, were detected in any patient during the study. No representative elevation of proinflammatory cytokines or plasma FGF-2 was seen. Significant and continuous improvements in Rutherford category, absolute claudication distance (ACD), and rest pain were observed (P %26lt; 0.05 to 0.01). To the best of our knowledge, this is the first clinical trial of the use of a gene transfer vector based on rSeV. The single intramuscular administration of DVC1-0101 to PAD patients was safe and well tolerated, and resulted in significant improvements of limb function. Larger pivotal studies are warranted as a next step.

• 出版日期2013-3